Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.

Summary

Lung cancer is a common disease leading to 18 % of cancer deaths worldwide. Despite various improvement in treatment, there still remains low 5-year survival rate of 10-20 % in advanced lung cancer patients. Skeletal muscle mass and physical performance have been shown to effect overall survival and prognosis in lung cancer. This research focuses on effects of different treatment of lung cancer such as chemotherapy, targeted therapy and immunotherapy on skeletal muscle mass and physical performance.

Eligibility

Inclusion Criteria:

1. Age \>18years old,
2. Stage IIIB and IIIC (if patients are treated with TKI/IO), and Stage IV non-small cell lung cancer patients confirmed by histopathology.
3. Patients should be either on chemotherapy, molecular targeted therapy or immunotherapy.

Exclusion Criteria:

1. Unable to perform CT scan due to various reasons.
2. Patients with metastatic disease at L3 vertebral level.
3. If unable to perform SPPB test due to physical disability or patient's refusal.
4. Patients with known other primary malignancies. 5 . Patients who have underwent definitive surgery.

6\. Pregnant patients. 7. Patients with physical deformities/neurological deficits which restricts their physical movements.

Conditions4

Interventions3

Related trials

• CIETAI and Sequential Radiotherapy in Squamous Lung Cancer — Dong Wang
• Clinical Observational Studies:Integrative TCM and Western Medicine for Breast Cancer — Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
• Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting — University Hospital, Strasbourg, France
• DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases — Tehran University of Medical Sciences
• Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer Using Zebra Fish Avatars — University Hospital, Linkoeping
• MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. — National Cancer Institute, Naples
• Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer — Chinese PLA General Hospital
• Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers — Immunocore Ltd

Browse More Trials